The researchers of the IISPV, the Hospital de Tortosa Verge de la Cinta and the Institut de l’Ebre who have made it possible will present this project yesterday at Investors Day, the closing event of two types of aid from the Knowledge Industry of the AGAUR
The TMAtech Molds, used in the field of research to analyze biopsy samples and investigate different pathologies, is one of the projects selected to be presented at the Investors Day conference, which took place this Thursday, January 23 in the Auditorium of the Faculty of Letters of the Autonomous University of Barcelona. The objective of this day is to close the support plan for the INNOVATORS 2022 and PRODUCTE 2023 grants of the University and Research Grants Management Agency (AGAUR) of the Generalitat de Catalunya. In addition, this conference also had the purpose of exposing different innovative initiatives with business potential that have arisen from scientific research, so that the results and findings made can have a significant impact on society. This event had the presence of investors specialized in financing projects arising from research, from both public and private funds, who analyzed the presentations and gave feedback to the projects.
The TMAtech Mold project is the result of a team of researchers from the Research Group on Oncological Pathology and Bioinformatics of the IISPV (PO&B, for its acronym and based at the Tortosa Verge de la Cinta Hospital) and professors from the Institute of Ebro (IE). The molds of TMAtech Mold are an improved and more innovative version of the silicone molds currently available on the market, which are used to construct tissue microarrays or TMA (by its acronym in English) to analyze in a cost-effective way the stains of the patient biopsies.
The innovation in the manufacturing process of these molds allows the simultaneous analysis of different tissue samples, helping to quickly identify markers that indicate the prognosis of a disease. Other advantages in relation to current molds are their lower cost, the possibility of a more personalized use and, when they are commercialized, their application not only in research, but also in health centers, thanks to obtaining a certification as a health product.
AGAUR, through Product aid, granted the team that is developing this technology 150,000 euros, as well as offering them a training plan so that they could train for a year in entrepreneurial, business and marketing skills, among others, to continue working in the project and commercialize the new molds in the market. Previously, the project had been financed by the Llavor grant with 50,000 euros and was also selected among the best projects to present at DemoDay 2023.
In addition, the TMAtech Mold project has also received funding from the GINJOL Patents Fund call, which supports the knowledge transfer projects of the CERCA centers. Thanks to this help, the team will be able to receive advice from consulting companies on intellectual property, business plan development, market and competitor studies, among others, which are key tools to successfully launch a project in the market.
Facebook 
Mail 
WhatsApp 
